Qualigen Inc. Competitors

Pile Dynamics, Inc. (PDI) develops testing, monitoring, and quality assurance technologies for the deep foundations industry. Since 1972, PDI has supported engineers, contractors, owners, and public agencies worldwide with equipment and software used to evaluate foundation performance and support quality assurance and quality control programs. PDI solutions are used for dynamic load testing, pile integrity testing, drilled shaft testing, foundation monitoring, wave equation analysis, thermal integrity testing, and ACIP/CFA pile installation monitoring. PDI technologies include the Pile Driving Analyzer® (PDA), CAPWAP®, GRLWEAP, ATLAS™ Secure Cloud Services, Thermal Integrity Profiler (TIP™), Pile Integrity Tester (PIT), Shaft Quantitative Inspection Device (SQUID™), Shaft Area Profile Evaluator (SHAPE®), CHAMP-Q, Saximeter-Q (SAX-Q), and other technologies that support deep foundation testing, monitoring, analysis, and quality assurance worldwide. Beyond its products, PDI contributes to the advancement of foundation engineering through research, technical publications, training programs, industry education, and the PDCA/PDI Dynamic Measurement and Analysis Proficiency Test, which supports professional development in dynamic foundation testing. PDI team members regularly lecture and share expertise on deep foundation testing and quality assurance. Headquartered in Cleveland, Ohio, PDI products are used in more than 100 countries and are supported by a worldwide network of representatives and technical professionals.

Introducing the TRACER 1000™: The World's First Mobile Mass Spectrometer Redefining Field Detection of explosives and narcotics. Elevate your security protocols with the TRACER 1000™, a revolutionary mobile mass spectrometer that seamlessly combines gold standard lab performance with unmatched field adaptability. The only mass spectrometer based ETD with both ECAC aviation certification and TSA Air Cargo approval, this cutting-edge technology offers unparalleled accuracy and system uptime to ensure precise and dependable detection in any setting. From bustling airports to rigorous border control, dynamic cargo inspections, and high-profile public events, the TRACER 1000™ thrives in the most demanding scenarios. Its portable and user-friendly design caters to the preferences of security professionals worldwide, guaranteeing swift and efficient operation. The TRACER 1000™ stands out as the sole explosives and narcotics trace detector on the market with limitless libraries that can be effortlessly updated to combat the latest threats. Unleash the power of precise detection with the TRACER 1000™, eliminating the disruption caused by false alarms and reducing operational costs. With a focus on delivering accurate results consistently, this advanced system minimizes false positives, ensuring your operations run smoothly without unnecessary interruptions. Investing in the TRACER 1000™ results in superior accuracy and zero downtime, reducing the impact of false alarms and operational disruptions, ultimately saving you time and resources in the long run. Opt for the TRACER 1000™ and experience unmatched accuracy in every application, proving its value day after day through unwavering performance and reliability. Choose excellence with the TRACER 1000™ and elevate your security measures to new heights.

BioMarker Strategies has developed the proprietary SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients. SnapPath® is unique in automating and standardizing functional ex vivo profiling to capture the dynamic and predictive signaling information available only from live solid tumor cells. Our PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatments for solid tumors, because they are based on information available only from live cells. Our business development efforts are directed toward entering into funded collaborations with companies developing targeted therapies for patients with solid tumors. The capabilities of SnapPath® and the Functional Profiles it enables are available for Research Use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients.